Phase II study of computed tomography-guided 125I-seed implantation plus chemotherapy for locally recurrent rectal cancer

Shi, Liangrong; Pei, Honglei; Zhao, Jiemin; Qiang, Weiguang; Wang, Jin; Xu, Bin; Chen, Lüjun; Wu, Jun; Ji, Mei; Lu, Qicheng; Li, Zhong; Wang, Haitao; Jiang, Jingting; Wu, Changping

doi:10.1016/j.radonc.2015.10.026

Cited by 7 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This therapy was initially used for the treatment of prostate cancer and has also been investigated in the treatment of other solid tumors in recent decades [7][8][9][10]. There are studies documenting its efficacy in terms of local tumor control [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Iodine-125 Seed Implantation in Locoregionally Recurrent and Unresectable Breast Cancer: a Retrospective Study

Wei

Qin

et al. 2017

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The management of locoregionally recurrent and unresectable breast cancer is a therapeutic challenge. This retrospective study aimed to assess the efficacy of 125 I seed implantation brachytherapy as a palliative management in locoregionally recurrent breast cancer. We analyzed 36 locoregionally recurrent and unresectable breast cancers in our hospital between 2012 and 2016. All patients were treated with CT-guided 125 I seed permanent implantation. The dose distribution of 125 I seeds was calculated using a computerized treatment planning system. Complete response, partial response, stable disease, and local tumor control rates were calculated. Long-term efficacy was assessed based on survival rates ranging from 1 to 4 years. The follow-up period ranged from 6 to 53 months. The median local control was 28 months (95% CI: 16.2-39.8 months). The percentage of patients who showed 6-month, 1-year, 2-year, and 3-year local control was 97.2%, 77.8%, 52.8%, and 33.3%, respectively. Median survival time for all patients was 48 months (95% CI: 40.9-55.1 months); 1-year, 2-year, 3-year, and 4-year survival rates were 97.2%, 80.6%, 63.9%, and 46.5%, respectively. Pain relief response rate was 88.9%. No serious complications were detected during the follow-up period. The results of this study demonstrate that 125 I seed implantation could be considered a feasible and promising minimally invasive therapy for locoregionally recurrent and unresectable breast carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Iodine-125 Seed Implantation in Locoregionally Recurrent and Unresectable Breast Cancer: a Retrospective Study

Wei

Qin

et al. 2017

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Initially, RISI is used to treat primary prostate cancer [ 30 , 31 , 32 , 33 ]. Accumulating evidence showed its good efficacy in various recurrent cancers, including rectal cancer, head and neck cancer, and pancreatic cancer [ 17 , 34 , 35 , 36 , 37 , 38 ]. Moreover, our previous studies demonstrated that 3D-PNCT-assisted CT-guided RISI is a safe, effective, and minimally invasive modality to treat recurrent cervical cancer after radiotherapy [ 16 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

PD-1 Inhibitor Maintenance Therapy Combined Iodine-125 Seed Implantation Successfully Salvage Recurrent Cervical Cancer after CCRT: A Case Report

Wei

Guo

et al. 2021

Current Oncology

View full text Add to dashboard Cite

Cervical cancer is the fourth most common cancer in females worldwide. Patients with stage III and IV cervical cancer based on the Federation of Gynecology and Obstetrics (FIGO) classification have higher recurrence rates. Because of organs at risk (OAR) protection and the low indication rate of salvage surgery, the choice of treatment is always challenging. Systemic chemotherapy is palliative and can be performed in conjunction with surgery or radiotherapy; however, it has no significant benefit to survival. Brachytherapy and stereotactic body radiotherapy (SBRT) are characterized by extremely high radiation doses applied to tumor cells while sparing the normal tissues. Several studies have investigated the efficacy of these technologies in recurrent cervical cancer and showed promising results. The immune checkpoint inhibitors approach was also investigated and showed promising results too. Herein, we report a case of a patient with cervical cancer that recurred five months after adjuvant chemotherapy and concurrent chemoradiotherapy. The disease prognosis after interstitial implantation brachytherapy (IIB) was determined. Then, the patient underwent radioactive 125I-seed implantation combined with PD-1 inhibitor treatment. The patient exhibited a partial response after seed implantation, and up to now, the duration of this partial response was 24 months.

show abstract

“…Compared with traditional radiotherapy, it has a more appropriate radiation radius to accurately treat the local area of lesions, and causes less trauma and damage to the normal tissue adjacent to lesions (19). In a study by Shi et al (20), the implantation of 125 I particles in patients with recurrent colorectal cancer significantly prolonged the survival time of the patients (21). In a study by Jiang et al (21), 56 lesions were treated through the implantation in patients with gastrointestinal cancer with pulmonary metastasis, with an overall local control rate of 91.1%.…”

Section: Discussionmentioning

confidence: 99%

Effects of radioactive 125I on apoptosis of HGC-27 gastric cancer cells

Yong

Chen

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Effects of radioactive 125I particles at different doses on apoptosis of HGC-27 gastric cancer cells were investigated. HGC-27 gastric cancer cell suspension was used to establish a tumor-bearing mouse model. The model was reared for approximately 3 weeks and then divided into the control group (implanted with blank particles), the low dose group (implanted with 1.48×10−7 Bq 125I particles), the medium dose group (implanted with 2.22×10−7 Bq 125I particles) and the high dose group (implanted with 2.96×10−7 Bq 125I particles) (n=15 per group). Six nude mice were randomly sacrificed to collect the tumor tissue and measure tumor volume and mass. TUNEL (TdT-mediated dUTP nick-end labeling) was used for detecting apoptosis of tumor cells, and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detecting the relative expression of Bax, caspase-3 and caspase-8. On the 28th day after implantation, the apoptotic rate in the low, medium and high dose groups was significantly higher than that in the control group, which in the medium and high dose groups was significantly lower than that in the low dose group (P<0.05). On the 28th day after implantation, the relative expression of Bax, caspase-3 and caspase-8 mRNA in the control group was significantly lower than that in the low, medium and high dose groups (P<0.05), which in the low dose group was significantly higher than that in the medium and high dose groups (P<0.05). 125I particles can inhibit the growth of HGC-27 gastric cancer cell transplants and promote the expression of Bax, caspase-3 and caspase-8 mRNA in the tumor tissue. Low-dose 125I particles are significantly more effective than medium- or high-dose 125I particles.

show abstract

Phase II study of computed tomography-guided 125I-seed implantation plus chemotherapy for locally recurrent rectal cancer

Cited by 7 publications

References 39 publications

Efficacy of Iodine-125 Seed Implantation in Locoregionally Recurrent and Unresectable Breast Cancer: a Retrospective Study

Efficacy of Iodine-125 Seed Implantation in Locoregionally Recurrent and Unresectable Breast Cancer: a Retrospective Study

PD-1 Inhibitor Maintenance Therapy Combined Iodine-125 Seed Implantation Successfully Salvage Recurrent Cervical Cancer after CCRT: A Case Report

Effects of radioactive 125I on apoptosis of HGC-27 gastric cancer cells

Contact Info

Product

Resources

About